Cite
HARVARD Citation
Moore, K. et al. (n.d.). 944PQUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. Annals of oncology. p. . [Online].